Repligen (RGEN) Soars 4.4%: Is Further Upside Left in the Stock?

Company Overview - Repligen (RGEN) shares increased by 4.4% to $125.32 in the last trading session, following a significant volume of shares traded, contrasting with a 24.4% loss over the past four weeks [1] - The company announced the promotion of Olivier Loeillot to president and CEO, effective September 1, 2024, which may have contributed to the recent share price increase [1] Earnings Expectations - Repligen is expected to report quarterly earnings of $0.33 per share, reflecting a year-over-year decline of 37.7% [2] - Revenue projections for the upcoming quarter are $154.32 million, down 3.1% compared to the same quarter last year [2] Stock Performance and Trends - The consensus EPS estimate for Repligen has remained unchanged over the last 30 days, indicating a lack of upward momentum in earnings estimate revisions [3] - The stock currently holds a Zacks Rank of 3 (Hold), suggesting a neutral outlook [3] - In the same industry, AnaptysBio, Inc. (ANAB) also holds a Zacks Rank of 3 (Hold) and saw a 4.9% increase in its last trading session [3][4]